用托法西提尼布治疗耐药性皮肤炎疹症的管理:一个病例报告
Armaghan Kazeminejad1, Fatemeh Montazer2, Mohammad Malekan3
1Department of Dermatology, Antimicrobial Resistance Research Center, Communicable Diseases Institute Mazandaran University of Medical Sciences Sari Iran.
Clinical case reports
|November 14, 2025
概括
托法西提尼布为皮肤炎形患者提供了安全有效的治疗选择,这些患者对标准疗法没有反应. 这种JAK抑制剂对难以治疗的自身免疫性皮肤疾病有希望.
科学领域:
- 免疫皮肤学 免疫皮肤学
- 自身免疫性皮肤疾病 自身免疫性皮肤疾病
- 在JAK-STAT路径上.
背景情况:
- 皮肤炎疹 (DH) 是一种慢性自身免疫性水泡性皮肤疾病.
- 达普森和无质饮食是DH的主要治疗方法.
- 一些患者表现出耐火性疾病,对传统疗法没有反应.
研究的目的:
- 评估托法西提尼布在患有对达普松和无质饮食耐药性皮肤炎的患者的疗效和安全性.
- 探索Janus激酶 (JAK) 抑制在管理自身免疫性皮肤疾病中的作用.
主要方法:
- 用托法西提尼布治疗的耐火性皮肤炎患者的案例研究/系列.
- 评估临床反应,不良事件和治疗持续时间.
主要成果:
- 托法西替尼在非响应性DH患者的皮肤病变和中显著改善.
- 治疗一般耐受良好,副作用可控.
- 在自身免疫性皮肤疾病的一个子集中,JAK抑制被证明有效.
结论:
- 托法西提尼布为耐火性皮肤炎herpetiformis提供了一个可行的治疗替代方案.
- 准JAK-STAT通路是针对自身免疫性皮肤疾病的一个有希望的策略.
- 需要进一步的研究,以在更大的队列中证实这些发现.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
473
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
473
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
420
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
420
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
470
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
470
Nephrotic Syndrome II : Assessment and Medical Management
187
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
187
Inflammatory Bowel Disease IV: Pharmacological Management
459
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
459

